Anders Hove Net Worth

The estimated Net Worth of Anders D Hove is at least $9.48 million dollars as of 27 April 2010. Anders Hove owns over 306,071 units of ARCA biopharma Inc stock worth over $9,477,768 and over the last 15 years he sold ABIO stock worth over $0. In addition, he makes $0 as Director at ARCA biopharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Anders Hove ABIO stock SEC Form 4 insiders trading

Anders has made over 1 trades of the ARCA biopharma Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently he bought 306,071 units of ABIO stock worth $3,366,781 on 27 April 2010.

The largest trade he's ever made was buying 306,071 units of ARCA biopharma Inc stock on 27 April 2010 worth over $3,366,781. On average, Anders trades about 51,012 units every 0 days since 2010. As of 27 April 2010 he still owns at least 3,949,070 units of ARCA biopharma Inc stock.

You can see the complete history of Anders Hove stock trades at the bottom of the page.

Anders Hove biography

Dr. Anders Hove, M.D., serves as Director of the Company. Dr. Hove was also appointed to serve on the Board’s Nominating and Corporate Governance Committee. Dr. Hove was most recently a general partner of Venrock Associates (“Venrock”), a venture capital firm, which he joined in January 2004. In 2008, Dr. Hove was a founder of Venrock Healthcare Capital Partners, Venrock’s public fund focused on small capitalization biotech companies and late-stage private companies. From 1996 to 2004, he was a fund manager at BB Biotech Fund, an investment firm, and from 2002 to 2003 he also served as Chief Executive Officer of Bellevue Asset Management, LLC, an investment company. Dr. Hove previously held senior level positions in the medical, clinical and business operations of the pharmaceuticals division of Ciba-Geigy. He has served on the Boards of Directors of numerous private and public companies, currently serving on the Boards of two private biopharmaceutical companies. Dr. Hove received a M.Sc. in Biotechnology Engineering from the Technical University of Denmark, an M.D. from the University of Copenhagen and an M.B.A. from the Institut Européen d'Administration des Affaires.

How old is Anders Hove?

Anders Hove is 50, he's been the Director of ARCA biopharma Inc since 2017. There are 12 older and no younger executives at ARCA biopharma Inc. The oldest executive at ARCA biopharma Inc is Dr. Michael R. Bristow M.D., Ph.D., 76, who is the Co-Founder, Pres, CEO & Director.

What's Anders Hove's mailing address?

Anders's mailing address filed with the SEC is 10170 CHURCH RANCH WAY, SUITE 100, WESTMINSTER, CO, 80021.

Insiders trading at ARCA biopharma Inc

Over the last 16 years, insiders at ARCA biopharma Inc have traded over $9,048,465 worth of ARCA biopharma Inc stock and bought 3,605,825 units worth $6,507,167 . The most active insiders traders include Forest Baskett, Scott D Sandell et Anthony A. Jr. Florence. On average, ARCA biopharma Inc executives and independent directors trade stock every 54 days with the average trade being worth of $636,994. The most recent stock trade was executed by Henderson Group Plc Janus H... on 16 August 2024, trading 5,818 units of ABIO stock currently worth $17,047.

What does ARCA biopharma Inc do?

arca was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. arca’s lead development program is intended to be a direct implementation of those ideas. gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (af). arca has identified genetic variations in cardiac receptors that we believe may predict individual patient response to gencaro™, giving gencaro™ the potential to be the first genetically-targeted prevention treatment for af.

Complete history of Anders Hove stock trades at Alimera Sciences et ARCA biopharma Inc

ARCA biopharma Inc executives and stock owners

ARCA biopharma Inc executives and other stock owners filed with the SEC include:

• Michael Bristow,
  President, Chief Executive Officer, Director
• Dr. Michael R. Bristow M.D., Ph.D.,
  Co-Founder, Pres, CEO & Director
• Thomas A. Keuer,
  Chief Operating Officer
• Christopher Ozeroff,
  Senior Vice President, General Counsel, Secretary
• Christopher D. Ozeroff,
  Sr. VP, Gen. Counsel & Sec.
• Raymond Woosley,
  Director
• Daniel Mitchell,
  Director
• Anders Hove,
  Director
• Linda Grais,
  Lead Independent Director
• Brian Selby,
  Chief Accounting Officer, Principal Accounting Officer, Vice President - Finance
• Thomas Keuer,
  Chief Operating Officer
• Robert Conway,
  Chairman of the Board
• Dr. Debra Marshall FACC, M.D.,
  Chief Medical Officer
• C. Jeffrey Dekker,
  Chief Financial Officer
• Henderson Group Plc Janus H...,
  
• Ravi Viswanathan,
  10% owner
• Scott D Sandell,
  10% owner
• David M Mott,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Peter J Barris,
  10% owner
• Healthcare Capital Partners...,
  
• Peter W. Sonsini,
  10% owner
• Jon Sakoda,
  10% owner
• Joshua Makower,
  10% owner
• Forest Baskett,
  10% owner
• Equity Opportunities Fund I...,
  
• Jean Francois Formela,
  Director
• Kathryn E Falberg,
  CFO and COO
• J William Freytag,
  Director
• Mary K Pendergast,
  Director
• Patrick M Wheeler,
  acting Chief Financial Officer
• Riley Mccormack,
  10% owner
• David George Lowe,
  Director
• Burton E Sobel,
  Director
• Venture Fund Vii L P Atlas,
  10% owner
• Richard B Brewer,
  Director
• John L Zabriskie,
  Director
• Venture Partners Qualified ...,
  10% owner
• Ted W Love,
  Director
• Funds, Lp Ma Weaver Jacob F...,
  
• Jacob Ma Weaver,
  
• Fund, Lp Funicular,
  
• C. Jeffrey Dekker,
  Chief Financial Officer
• Fund, Lp Ma Weaver Jacob Fu...,
  
• Funds, Lp Funicular,
  10% owner
• James P Flynn,
  Director